Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
World game at war: why some European nations have threatened a World Cup boycott 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
TUCSON, Ariz., April 27, 2018 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter ended March 31, 2018 after the market close on Thursday, May 10. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
| Conference Call & Webcast Details | ||
| Date: | Thursday, May 10 | |
| Time: | 4:30pm Eastern Time | |
| Toll Free: | 866-548-4713 | |
| International: | 323-794-2093 | |
| Conference ID: | 5477857 | |
| Webcast: | http://public.viavid.com/index.php?id=129155 | |
About HTG:
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
CONTACT:
Ashley Robinson
LifeSci Advisors, LLC
617-775-5956
[email protected]
TJ Johnson
President/CEO
HTG Molecular Diagnostics
520-547-2827 x130
[email protected]
